Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00636870 · ClinicalTrials.gov registry record · Phase 4
Fexofenadine (Allegra®) in Healthy Adults Who Have Been Identified as Slow Metabolizers for Desloratadine
A Phase 4 study of Allergic Rhinitis, sponsored by Sanofi.
- Completed
- Registry status
- Phase 4
- Development phase
- 220
- Enrollment target
- 1
- Study location
NCT00636870 is a Phase 4 study of Allergic Rhinitis that has completed, run by Sanofi. The registered enrollment target is 220 participants, above the 96-participant average among 23 other Allergic Rhinitis trials with a reported enrollment target (129% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00636870, a Phase 4 study of Allergic Rhinitis, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 220 participants
- Enrollment target
- 1
- Study location
Study Summary
To evaluate the single-dose and steady-state pharmacokinetics of desloratadine and fexofenadine in desloratadine slow metabolizers. To evaluate the safety and tolerability of desloratadine compared to fexofenadine following single and multiple oral doses administered to desloratadine slow metabolizers.
Conditions Studied
Interventions
- DRUG Fexofenadine
Study Locations (1)
New Jersey
- Sanofi-Aventis - Bridgewater
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2003-02 |
| Est. Completion | 2004-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00636870
The ClinicalTrials.gov registry entry for NCT00636870 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 96-participant average among 23 other Allergic Rhinitis trials with a reported enrollment target (129% higher). The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Allergic Rhinitis appearing as the primary indexed condition, and to 1 intervention - of which Fexofenadine is the first listed.
NCT00636870 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT00636870 about?
NCT00636870 is a clinical study titled "Fexofenadine (Allegra®) in Healthy Adults Who Have Been Identified as Slow Metabolizers for Desloratadine". To evaluate the single-dose and steady-state pharmacokinetics of desloratadine and fexofenadine in desloratadine slow metabolizers. To evaluate the safety and tolerability of desloratadine compared to fexofenadine following single and multiple oral doses administered to desloratadine slow metabolize...
What is the current status of trial NCT00636870?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 220 participants. The study started on 2003-02. Estimated completion is 2004-01.
What conditions does trial NCT00636870 study?
This clinical trial studies the following conditions: Allergic Rhinitis.
What interventions are being tested in trial NCT00636870?
The interventions under investigation include: Fexofenadine (DRUG).
Who is sponsoring clinical trial NCT00636870?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00636870 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Allergic Rhinitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Repurposed Use of Allergic Rhinitis and Allergic Asthma Drug to Reduce Vertigo and Hearing Loss in Meniere's Disease
ACTIVE NOT RECRUITING · Phase 4
-
Fexofenadine HCl 180 mg, Desloratadine 5 mg and Placebo in Suppression of Wheal and Flare Induced by Histamine
COMPLETED · Phase 4
-
The Effect of Cetirizine on Bronchoconstriction
COMPLETED · Phase 4
-
Comparability and Standardization of Controlled Allergen Challenge Facilities
COMPLETED · Phase 4
-
Immunologic Basis of Anti-IgE Therapy (Study II: On Patients With Asthma)
COMPLETED · Phase 4
-
Comparison Between Systemic Exposure to Ciclesonide Nasal Spray, Ciclesonide HFA Nasal Aerosol and Orally Inhaled Ciclesonide (BY9010/M1-422)
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.